Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of the first data from the Phase 3
clinical development program for omarigliptin, Merck’s investigational
once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes.
for Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes investment picks